DGX vs PHIO · P/E 22, rev $5.94B vs $10.4M cap
Quest Diagnostics Incorporated (DGX) versus Phio Pharmaceuticals Corp (PHIO) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Phio Pharmaceuticals Corp (PHIO) is a biotechnology company listed on US.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
PHIO does not have a complete income-statement cache yet.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. PHIO currently screens at market cap $10.4M.
Not investment advice. Open the DGX and PHIO stock pages for the full models.
Not investment advice.